Autoimmune hemolytic anemia, warm type
disease diseaseOn this page
Also known as wAHAwAIHAwarm AIHAwarm antibody AIHAwarm antibody autoimmune hemolytic anaemiawarm antibody autoimmune hemolytic anemiawarm antibody hemolytic anaemiawarm antibody hemolytic anemiaWarm Autoimmune Hemolytic Anemiawarm-reacting-antibody hemolytic anaemiawarm-reacting-antibody hemolytic anemia
Summary
Autoimmune hemolytic anemia, warm type (MONDO:0019532) is a disease and 26 clinical trials. Top therapeutic interventions include fostamatinib disodium, acalabrutinib, and isatuximab. A subtype of autoimmune hemolytic anemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Europe)
- Phenotypes (HPO): 27
- Clinical trials: 26
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
27 HPO clinical features (Orphanet curated; top 27 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000980 | Pallor | Very frequent (80-99%) |
| HP:0001890 | Autoimmune hemolytic anemia | Very frequent (80-99%) |
| HP:0002315 | Headache | Very frequent (80-99%) |
| HP:0002875 | Exertional dyspnea | Very frequent (80-99%) |
| HP:0002960 | Autoimmunity | Very frequent (80-99%) |
| HP:0012378 | Fatigue | Very frequent (80-99%) |
| HP:0001744 | Splenomegaly | Frequent (30-79%) |
| HP:0001923 | Reticulocytosis | Frequent (30-79%) |
| HP:0001962 | Palpitations | Frequent (30-79%) |
| HP:0002829 | Arthralgia | Frequent (30-79%) |
| HP:0003641 | Hemoglobinuria | Frequent (30-79%) |
| HP:0004835 | Microspherocytosis | Frequent (30-79%) |
| HP:0005523 | Lymphoproliferative disorder | Frequent (30-79%) |
| HP:0008282 | Unconjugated hyperbilirubinemia | Frequent (30-79%) |
| HP:0020062 | Decreased hemoglobin concentration | Frequent (30-79%) |
| HP:0020181 | Reduced haptoglobin level | Frequent (30-79%) |
| HP:0025435 | Increased circulating lactate dehydrogenase concentration | Frequent (30-79%) |
| HP:0032366 | Positive direct antiglobulin test | Frequent (30-79%) |
| HP:0000952 | Jaundice | Occasional (5-29%) |
| HP:0001635 | Congestive heart failure | Occasional (5-29%) |
| HP:0001649 | Tachycardia | Occasional (5-29%) |
| HP:0001945 | Fever | Occasional (5-29%) |
| HP:0002725 | Systemic lupus erythematosus | Occasional (5-29%) |
| HP:0005550 | Chronic lymphatic leukemia | Occasional (5-29%) |
| HP:0012086 | Abnormal urinary color | Occasional (5-29%) |
| HP:0030848 | Elevated jugular venous pressure | Occasional (5-29%) |
| HP:0100749 | Chest pain | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | autoimmune hemolytic anemia, warm type |
| Mondo ID | MONDO:0019532 |
| Orphanet | 90033 |
| ICD-10-CM | D59.11 |
| ICD-11 | 880772122 |
| NCIT | C162611 |
| SNOMED CT | 3978000 |
| UMLS | C0272118 |
| MedGen | 450541 |
| GARD | 0007876 |
| MedDRA | 10047822 |
| NORD | 1837 |
| Is cancer (heuristic) | no |
Also known as: wAHA · wAIHA · warm AIHA · warm antibody AIHA · warm antibody autoimmune hemolytic anaemia · warm antibody autoimmune hemolytic anemia · warm antibody hemolytic anaemia · warm antibody hemolytic anemia · Warm Autoimmune Hemolytic Anemia · warm-reacting-antibody hemolytic anaemia · warm-reacting-antibody hemolytic anemia
Data availability: 6 cell lines.
Disease family
This is a subtype of autoimmune hemolytic anemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › hematologic disorder › autoimmune disorder of blood › autoimmune hemolytic anemia › autoimmune hemolytic anemia, warm type
Related subtypes (6): Evans syndrome, autoimmune hemolytic anemia, cold type, neonatal autoimmune hemolytic anemia, mixed-type autoimmune hemolytic anemia, drug-induced autoimmune hemolytic anemia, giant cell hepatitis with autoimmune hemolytic anemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 26.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 12 |
| PHASE3 | 6 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
| Not specified | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04119050 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia |
| NCT04138927 | PHASE3 | ENROLLING_BY_INVITATION | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia |
| NCT05535933 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia |
| NCT05648968 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia |
| NCT05786573 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) |
| NCT01181154 | PHASE3 | COMPLETED | Rituximab in Auto-Immune Hemolytic Anemia |
| NCT03764618 | PHASE3 | COMPLETED | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA |
| NCT05073458 | PHASE3 | TERMINATED | Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia |
| NCT04657094 | PHASE2 | ACTIVE_NOT_RECRUITING | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia |
| NCT05002777 | PHASE2 | ACTIVE_NOT_RECRUITING | Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) |
| NCT05757570 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias |
| NCT07039422 | PHASE2 | RECRUITING | Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab |
| NCT07549698 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease |
| NCT02612558 | PHASE2 | COMPLETED | A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) |
| NCT03075878 | PHASE1/PHASE2 | TERMINATED | A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) |
| NCT03226678 | PHASE2 | COMPLETED | Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) |
| NCT03965624 | PHASE2 | WITHDRAWN | Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia |
| NCT04253236 | PHASE2 | TERMINATED | To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). |
| NCT04256148 | PHASE2 | WITHDRAWN | ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia |
| NCT04661033 | PHASE2 | TERMINATED | Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA) |
| NCT04691570 | PHASE2 | COMPLETED | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) |
| NCT04956276 | PHASE2 | WITHDRAWN | Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia |
| NCT05922839 | PHASE2 | UNKNOWN | Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA |
| NCT02502903 | PHASE1 | COMPLETED | Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders |
| NCT05925023 | Not specified | RECRUITING | Sirolimus in the Treatment of Refractory/Relapsed wAIHA |
| NCT05221619 | Not specified | TEMPORARILY_NOT_AVAILABLE | Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FOSTAMATINIB DISODIUM | 4 | 2 |
| ACALABRUTINIB | 4 | 1 |
| ISATUXIMAB | 4 | 1 |
| IXAZOMIB CITRATE | 4 | 1 |
| PEGCETACOPLAN | 4 | 1 |
| RITUXIMAB | 4 | 1 |
| ZANUBRUTINIB | 4 | 1 |
| IANALUMAB | 3 | 2 |
| NIPOCALIMAB | 3 | 2 |
| ANX-005 | 3 | 1 |
| BATOCLIMAB | 3 | 1 |
| IXAZOMIB | 3 | 1 |
| OBEXELIMAB | 3 | 1 |
| RILZABRUTINIB | 3 | 1 |
| ORILANOLIMAB | 2 | 3 |
| POVETACICEPT | 2 | 1 |
| CHEMBL4747506 | 0 | 1 |
| CHEMBL5187554 | 0 | 1 |
| CHEMBL5276925 | 0 | 1 |
| CHEMBL5193128 | 0 | 1 |